Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for CliniciansTommaso Lupia, Lorenzo Cani, Sara Bringhen, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple MyelomaLorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Frontiers in Oncology|December 6, 2021
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference CenterDavide Tore, Osvaldo Rampado, Carla Guarnaccia, et al.
Annals of Hematology|February 13, 2025
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian expertsMattia D'Agostino, Marina Martello, Lorenzo De Paoli, et al.
Frontiers in Oncology|April 1, 2022
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple MyelomaFrancesca Bonello, Serena Rocchi, Gregorio Barilà, et al.
Acta Haematologica|March 26, 2014
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma NetworkShuji Ozaki, Takeshi Harada, Takayuki Saitoh, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2026
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life ApplicationRoberto Mina, Elisabetta Antonioli, Gregorio Barilà, et al.
Annals of Hematology|January 4, 2021
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myelomaStefania Oliva, Lorenzo De Paoli, Marina Ruggeri, et al.
Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.
Pageof 8